查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197098

HDL 胆固醇套件市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

HDL Cholesterol Kits Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，HDL 胆固醇试剂盒市场预计将以 6.2% 的复合年增长率增长。

COVID-19 大流行的出现对全球经济和医疗保健系统产生了负面影响。 在 COVID-19 大流行期间，具有潜在风险和肥胖的人面临更大的风险。 例如，根据疾病预防控制中心 2021 年 3 月发布的数据，所有 COVID-19 住院治疗中约有 30.2% 归因于肥胖。 在大流行期间，肥胖呈指数级增长。 例如，2021 年 8 月发表在《糖尿病、肥胖和新陈代谢》(Diabetes, Obesity and Metabolism) 上的一篇论文表明，肥胖的流行是 COVID-19 全国病例和死亡率增加的一个重要且可改变的风险因素。 COVID-19 流行病影响了市场的增长，因为它限制了医院和诊所的患者就诊，并减少了进行的胆固醇测试的数量。 但是，由于解除限制和恢復服务，预计在预测期内市场将增加。

胆固醇检测对肥胖、高脂血症和糖尿病患者的重要性日益增加，并且提高对高风险胆固醇的认识计划预计将推动市场增长。

在过去几十年中，肥胖症的发病率急剧上升，尤其是在发达国家和发展中国家，这些国家的生活方式疾病如焦虑、压力、吸烟和饮酒十分普遍。它有时被称为地方病。 肥胖也是 2 型糖尿病、心血管疾病和高血压的重要危险因素，并且与阿尔茨海默病等脑部疾病有关。 例如，根据世界卫生组织公布的2021年数据，估计有3820万五岁以下儿童超重或肥胖。 随着儿童食用更多的垃圾食品和加工食品，预计体内的维生素会减少，患上高胆固醇的风险也会增加。 因此，定期筛查胆固醇水平的需求将会增加，预计这将在预测期内推动市场增长。

同样，根据 2022 年世界肥胖地图集数据，预计到 2030 年印度将有 2700 万儿童肥胖。 因此，肥胖会增加因不健康饮食、缺乏锻炼和糖尿病等潜在疾病而患上高胆固醇的风险。 因此，在预测期内，为降低患心血管疾病风险而增加的胆固醇检测需求预计将推动 HDL 胆固醇检测试剂盒的增长。

此外，根据 2021 年 2 月的一篇文章，血脂异常是心血管疾病的主要危险因素。 此外，在梅克尔市的成年人口中发现血脂异常的高发率高得令人无法接受，这凸显了在政府、非政府和公共实体的协调参与下进行早期检测和公共卫生干预的迫切需要。 预计这将增加居民对早期检测胆固醇的需求，以避免患上各种慢性病的风险。 因此，上述所有因素都有望推动市场增长。

但是，HDL 胆固醇检测方法中的错误和不准确可能会阻碍预测期内的市场增长。

高密度脂蛋白胆固醇试剂盒市场趋势

在预测期内，HDL 和 LDL/VLDL 检测试剂盒部分有望主导 HDL 胆固醇试剂盒市场

高密度脂蛋白和低密度脂蛋白/极低密度脂蛋白检测试剂盒市场的增长是由于肥胖和高脂血症患者数量的增加、心血管疾病在人群中的患病率增加、技术进步以及对胆固醇筛查和检测方法的认识不断提高。在预测期内，高密度脂蛋白胆固醇市场将显着增长。

HDL 和 LDL/VLDL 检测试剂盒提供 HDL 和 LDL/VLDL 胆固醇的定量比色测定。 脂蛋白是冠状动脉疾病的有力预测指标。 功能性 HDL 通过去除细胞和斑块中的胆固醇发挥保护作用。 由于动脉硬化的风险增加，高 LDL 水平和低功能性 HDL 水平与心血管疾病密切相关。 高密度脂蛋白和低密度脂蛋白之间的平衡主要由基因决定，但也可能因药物和食物选择等因素而改变。

根据经合组织发布的 2021 年数据，到 2030 年，预计美国约有 47% 的人口、墨西哥约有 39% 的人口和加拿大约有 35% 的人口患有肥胖症。 因此，预计肥胖人数的增加将增加对胆固醇检测的需求，预计这将在预测期内推动细分市场的增长。

同样，墨西哥人口中的吸烟和肥胖被发现是心脏病最常见的危险因素，这也促进了预测期内所研究市场的增长。 例如，根据世界肥胖联合会发布的2022年统计数据，2020年墨西哥有31.5%的男性和40.2%的女性被确认患有肥胖症。

此外，不断增长的老年人口更容易患上胆固醇和心血管疾病，推动了对胆固醇检测试剂盒和化验的需求，预计这将推动市场增长，从而促进市场增长。 例如，根据UNPF公布的2022年统计数据，2022年德国15岁至64岁人口将占总人口的64%，65岁及以上人口将占22%。 据同一消息来源称，在墨西哥，67%的人口年龄在15-64岁之间，8%的人口年龄在65岁以上。

此外，根据 2021 年 6 月的一篇文章，在法国，肥胖会增加患上糖尿病和高血压等慢性疾病的可能性，并且会产生严重的心理和社会影响。这被认为是一个公共卫生问题。 结果，肥胖的人需要更多的血液来为他们的身体提供氧气和营养，因此肥胖的流行增加了脂肪在动脉中堆积的风险以及发生心律失常等各种心脏病的风险增加。 因此，上述因素预计将增加对胆固醇检测试剂盒的需求，并在预测期内推动市场增长。

北美主导市场，预计在预测期内也会如此

北美的高密度脂蛋白胆固醇有望主导市场。

肥胖、高脂血症及其相关风险的日益流行是推动市场增长的关键因素。 例如，根据 2021 年 1 月更新的 AHA 数据，大约 45% 的美国人口将因超重、大量吸烟和不健康的生活方式等因素而患上心脏病，而到 2035 年，心脏病发作等可能导致有关的问题

此外，该地区高昂的医疗费用也促进了市场的增长。 例如，康哲药业2022年3月发布的数据证实，2021年至2030年国民医疗支出年均增长率为5.1%。 2020年，全国医疗保健支出为4.1万亿美元，预计2030年将达到6.8万亿美元。 因此，预计医疗保健支出的增加将增加企业活动和政府在开发技术先进的检测设备和分析方面的举措，从而推动对胆固醇检测试剂盒的需求。

此外，企业在开发测试胆固醇的产品方面的活动增加也有助于市场增长。 例如，2021 年 2 月，Verichem Laboratories 推出了一种液体稳定的即用型 HDL 胆固醇验证试剂盒，旨在校准高密度脂蛋白 (HDL) 和低密度脂蛋白 (LDL) 胆固醇测定。 这些试剂盒可满足广泛的临床实验室专业人员的需求，包括常规诊断测试、医学研究应用以及体外诊断 (IVD) 製造和支持。 该试剂盒包含来自人血清的 HDL 和 LDL 胆固醇以及其他脂质成分，不含表面活性剂、乙二醇、迭氮化物或其他潜在干扰物质。

因此，上述所有因素预计将在预测期内推动北美市场的增长。

HDL 胆固醇试剂盒市场竞争者分析

HDL 胆固醇试剂盒市场竞争激烈，由几家主要参与者组成。 被调查市场的主要参与者正专注于通过分销协议和开设新的製造工厂来扩大其在亚太地区、中东和欧洲的业务。 目前主导市场的公司包括 Abbott、Randox Laboratories Ltd、Thermo Fisher Scientific、Abcam PLC、Merck KGaA、PerkinElmer Inc、Diazyme Laboratories Inc、Cell Biolabs Inc、Oscar Medicare Pvt.Ltd.。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 肥胖、高脂血症和糖尿病患者的胆固醇筛查越来越重要
    • 提高对高风险胆固醇的认识计划
  • 市场製约因素
    • 高密度脂蛋白胆固醇测试方法的错误和不准确
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品类型
    • HDL 和 LDL/VLDL 检测试剂盒
    • HDL 胆固醇直接试剂盒
  • 最终用户
    • 医院
    • 诊断机构
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Randox Laboratories Ltd
    • Thermo Fisher Scientific
    • Abcam PLC
    • Merck KGaA
    • PerkinElmer Inc.
    • Diazyme Laboratories Inc.
    • Cell Biolabs Inc.
    • Oscar Medicare Pvt. Ltd

第7章 市场机会与今后动向

简介目录
Product Code: 68587

The HDL cholesterol kits market is poised to grow at a CAGR of 6.2% over the forecast period.

The emergence of the COVID-19 pandemic has had an adverse effect on the world economy and the healthcare system. People with underlying risk conditions and obesity were at greater risk during the COVID-19 pandemic. For instance, as per the data published by the CDC in March 2021, around 30.2% of the total COVID-19 hospitalizations were attributed to obesity. It was observed that obesity had increased exponentially during the pandemic. For instance, an article published in Diabetes, Obesity and Metabolism in August 2021 showed that obesity prevalence is a significant and potentially modifiable risk factor for increased COVID-19 national caseload and mortality. The COVID-19 pandemic restricted patient visits in hospitals and clinics, which decreased the number of cholesterol testing procedures and hence impacted market growth. However, with the release of restrictions and resumed services, the market is expected to increase over the forecast period.

The growing importance of cholesterol screening in obese, hyperlipidemic, and diabetic populations, as well as growing awareness programs for high-risk cholesterol, are expected to drive market growth.

The incidence of obesity has been increasing fiercely over the past decades, and it is often described as a global endemic, especially in developed and developing countries where lifestyle-related disorders, such as anxiety, stress, smoking, and drinking, are more prevalent. Also, obesity is a key risk factor for type 2 diabetes, cardiovascular disease, and hypertension, and it has also been linked to brain illnesses like Alzheimer's disease. For instance, according to the 2021 data published by the WHO, an estimated 38.2 million children under the age of 5 were overweight or obese in 2021. The increasing consumption of junk and processed foods by children decreases the number of vitamins in the body, which is expected to increase the risk of developing high cholesterol. This raises the need to routinely screen cholesterol levels, which is anticipated to propel market growth over the forecast period.

Similarly, according to World Obesity Atlas data from 2022, 27 million children in India are expected to be obese by 2030. Thus, obesity increases the risk of developing high cholesterol due to an unhealthy diet, a lack of exercise, and underlying conditions such as diabetes. This is expected to increase the demand for cholesterol testing in order to reduce the risk of developing cardiovascular disease, fueling the growth of HDL cholesterol test kits over the forecast period.

Furthermore, according to a February 2021 article, dyslipidemia is a major risk factor for cardiovascular disease. Furthermore, an unacceptably high incidence of dyslipidemia has been discovered in Mekelle City's adult population, emphasizing the critical need for early detection and public health interventions through the coordinated involvement of governmental, non-governmental, and public groups. This is expected to increase the population's need for early detection of cholesterol in order to avoid the risks of developing various chronic diseases. Therefore, all the aforementioned factors are expected to fuel market growth.

However, the errors and inaccuracies in HDL cholesterol testing methods are likely to impede the market's growth over the forecast period.

HDL Cholesterol Kits Market Trends

HDL and LDL/VLDL Assay Kit Segment is Expected to Dominate the HDL Cholesterol Kits Market Over the Forecast Period

The HDL and LDL/VLDL assay kit segment is expected to grow significantly in the HDL cholesterol market over the forecast period due to an increase in obesity and hyperlipidemia cases, an increase in the prevalence of cardiovascular diseases among the population, technological advancements, and increased awareness about cholesterol screening and testing procedures.

The HDL and LDL/VLDL assay kit is a quantitative colorimetric determination of HDL and LDL/VLDL cholesterol. Lipoproteins are strong predictors of coronary heart disease. Functional HDL offers protection by removing cholesterol from cells and atheroma. Higher concentrations of LDL and lower concentrations of functional HDL are strongly associated with cardiovascular disease due to a higher risk of atherosclerosis. The balances between high and low-density lipoproteins are solely genetically determined but can be changed by medications, food choices, and other factors.

According to the 2021 data published by the OECD, about 47% of the population in the United States, 39% in Mexico, and 35% in Canada are expected to suffer from obesity by 2030. As a result, the expected high number of obese people raises the demand for cholesterol testing, which is expected to drive segment growth over the forecast period.

Similarly, smoking and obesity in the Mexican population are found to be the most prevalent heart disease risk factors, which are also contributing to the growth of the market studied over the forecast period. For instance, according to 2022 statistics published by the World Obesity Federation, it has been observed that 31.5% of men and 40.2% of women were living with obesity in Mexico in 2020.

Furthermore, the growing geriatric population is contributing to market growth because they are more likely to develop cholesterol and cardiovascular diseases, which is expected to fuel demand for cholesterol testing kits and assays, boosting market growth. For instance, according to the 2022 statistics published by the UNPF, in 2022, in Germany, a large proportion is aged 15-64 and accounts for 64% of the population, while 22% of the population is aged 65 years and above. Also, as per the same source, in Mexico, a large proportion of the living population is aged 15-64 and accounts for 67% of the population, while 8% of the population is aged 65 years and above.

Furthermore, according to a June 2021 article, obesity is considered a serious public health issue in France because it increases the likelihood of developing chronic conditions such as diabetes, hypertension, and other conditions with severe psychological and social consequences. As a result, the prevalence of obesity raises the risk of developing a variety of heart ailments, such as fatty buildup in the arteries, irregular heartbeats, and other issues, because obese people require more blood to provide oxygen and nutrition to the body. Thus, the aforesaid factors are expected to increase demand for cholesterol testing kits, which is anticipated to propel market growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the HDL cholesterol market over the forecast period due to factors such as rising obesity and hyperlipidemia rates among the population, increasing technological advancements in cholesterol detection products, the presence of well-established healthcare infrastructure, and the region's high healthcare expenditure.

The increasing prevalence of obesity, hyperlipidemia, and associated risks is the key factor driving market growth. For instance, according to the AHA data updated in January 2021, around 45% of the United States population is likely to suffer from heart disease due to factors like high obesity, high smoking, and unhealthy lifestyles, which may lead to heart attacks and other related issues by 2035.

In addition, the high healthcare expenditure in the region is also contributing to market growth. For instance, as per the data published by the CMS in March 2022, it has been observed that the annual growth in national health spending is expected to be an average of 5.1% over 2021-2030. Also, the national health spending in 2020 was USD 4.1 trillion, and it was projected to reach USD 6.8 trillion by 2030. Thus, the increasing healthcare spending is expected to increase company activities and government initiatives in developing technologically advanced testing devices and assays, thereby propelling the demand for cholesterol testing kits.

Furthermore, the rising company activities in developing products for testing cholesterol also contribute to the market's growth. For instance, in February 2021, Verichem Laboratories launched a liquid-stable and ready-to-use HDL Cholesterol Verifier Kit intended to calibrate both High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) cholesterol assays. The kit meets the needs of a wide variety of clinical laboratory professionals, including those involved in routine diagnostic testing, medical research applications, and the manufacturing and support of in-vitro diagnostic (IVD) products. The kit contains HDL and LDL cholesterol and other lipid components from human serum free of surfactants, glycols, azide, and other potential interfering substances.

Thus, all the aforementioned factors are expected to propel market growth in North America over the forecast period.

HDL Cholesterol Kits Market Competitor Analysis

The HDL cholesterol kit market is moderately competitive and consists of several major players. The major players in the market studied are focusing on expanding their presence in the Asia-Pacific, the Middle East, and Europe through distribution agreements and the opening of new manufacturing facilities. Some of the companies that are currently dominating the market are Abbott, Randox Laboratories Ltd, Thermo Fisher Scientific, Abcam PLC, Merck KGaA, PerkinElmer Inc., Diazyme Laboratories Inc., Cell Biolabs Inc., and Oscar Medicare Pvt. Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Importance of Cholesterol Screening in the Obese, Hyperlipidemic, and Diabetic Population
    • 4.2.2 Growing Awareness Programs for High-Risk Cholesterol
  • 4.3 Market Restraints
    • 4.3.1 Errors and Inaccuracy in HDL Cholesterol Testing Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 HDL and LDL/VLDL Assay Kit
    • 5.1.2 HDL Cholesterol Direct Reagent Kit
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Randox Laboratories Ltd
    • 6.1.3 Thermo Fisher Scientific
    • 6.1.4 Abcam PLC
    • 6.1.5 Merck KGaA
    • 6.1.6 PerkinElmer Inc.
    • 6.1.7 Diazyme Laboratories Inc.
    • 6.1.8 Cell Biolabs Inc.
    • 6.1.9 Oscar Medicare Pvt. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS